Jose Ruiz-Iglesias

Jose Ruiz-Iglesias

Auto-generated profile, based on publicly available information

Jose Ruiz-Iglesias

Molecular Neuropathology Unit, Physiological and Pathological Processes Program Centro de Biología Molecular Severo Ochoa, CSIC‐UAM Madrid Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2026 in European Journal of Neuroscience
Verified
Journal Article
Open access
LCLucía Cañizares‐Moscato
Lucía Cañizares‐Moscato
JRJose Ruiz‐Iglesias
Jose Ruiz‐Iglesias
JIJavier Isoler‐Alcaraz
Javier Isoler‐Alcaraz
EPErnest Palomer
Ernest Palomer
Alzheimer's disease (AD) is a complex neurodegenerative disorder in which most risk variants are noncoding and are enriched at gene regulatory regions, implicating epigenetic mechanisms as central mediators of disease pathogenesis. For most of the history of AD epigenetics research, bulk tissue analysis has dominated, obscuring the fundamentally distinct epigenomic landscapes of individual brain cell types and masking cell‐type‐specific contributions to disease. Advances in single‐cell and single‐nucleus sequencing, fluorescence‐activated nuclei sorting and multiplexed epigenomic platforms have transformed this landscape, enabling cell‐type‐resolved profiling of chromatin accessibility, DNA methylation, histone modifications and transcription across the major neuronal, glial and neurovascular populations of the human brain. Here, we review these advances, structured around the argument that cell‐type resolution is not a methodological refinement but a conceptual necessity. We describe the distinct epigenomic programs disrupted in neurons, microglia, astrocytes, oligodendrocytes and neurovascular cells in AD, highlighting how each cell type responds to pathology. We discuss the discovery of epigenomic erosion, the progressive loss of cell‐type‐specific epigenomic identity across virtually all brain cell populations as AD advances, as a unifying disease mechanism linking chromatin dysregulation to cognitive decline. Finally, we identify critical gaps in current knowledge, including the near‐complete absence of cell‐type‐resolved histone modification and DNA methylation data for most brain cell types, the underrepresentation of rare populations in standard preparations and the untapped potential of metabolic acylation marks as indicators of the epigenome–metabolism interface in neurodegeneration.

18 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JRJose Ruiz-Iglesias
Jose Ruiz-Iglesias
EBElena R. Bovolenta
Elena R. Bovolenta
LCLucía Cañizares-Moscato
Lucía Cañizares-Moscato
JIJavier Isoler-Alcaraz
Javier Isoler-Alcaraz
LMLucía Martín-Rodriguez
Lucía Martín-Rodriguez
EPErnest Palomer
Ernest Palomer
The epigenetic landscape of individual cells determines their identity and function, yet current methods for profiling chromatin modifications at single-cell resolution remain low-throughput, costly, or limited in parametric depth. Here we present EpiFlow, a spectral flow cytometry-based platform that enables the simultaneous quantification of 16 epigenetic markers, including histone post-translational modifications, DNA methylation, and hydroxymethylation, at the single-cell level. We demonstrate that EpiFlow is robust across species from yeast to mammals and resolves biologically meaningful epigenetic transitions during the cell cycle, stem cell differentiation, germinal centre B cell maturation, diabetic liver remodelling, and seizure-induced chromatin reprogramming. High-dimensional integration of EpiFlow data enables cell-type classification based solely on epigenetic profiles in liver, brain, blood, and cancer. Furthermore, EpiFlow detects on-target and off-target/indirect effects of epigenetic drugs in a high-throughput-compatible format. Collectively, these results establish EpiFlow as a broadly applicable platform for single-cell epigenetic analysis in basic, pharmaceutical, and translational research.